Fate Therapeutics バランスシートの健全性
財務の健全性 基準チェック /66
Fate Therapeuticsの総株主資本は$362.3M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$495.0Mと$132.6Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$296.92m |
| エクイティ | US$362.33m |
| 負債合計 | US$132.64m |
| 総資産 | US$494.97m |
財務の健全性に関する最新情報
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Recent updates
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01財務状況分析
短期負債: FATEの 短期資産 ( $310.3M ) が 短期負債 ( $37.4M ) を超えています。
長期負債: FATEの短期資産 ( $310.3M ) が 長期負債 ( $95.2M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: FATEは負債がありません。
負債の削減: FATE負債比率が5.2%であった 5 年前と比べて負債がありません。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: FATEは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。
キャッシュランウェイの予測: FATEは、フリー キャッシュ フローが毎年22.1 % の歴史的率で減少し続ける場合、 1.8年間十分なキャッシュ ランウェイを有しています。